BHC
Get informed when a big investor buys or sells
+ FollowUndervalued by 82.5% based on the discounted cash flow analysis.
| Market cap | $2.58 Billion |
|---|---|
| Enterprise Value | $2.54 Billion |
| Dividend Yield | $1.28 (-) |
| Earnings per Share | $0.43 |
| Beta | 0.42 |
| Outstanding Shares | 375,000,000 |
| P/E Ratio | -2.34 |
|---|---|
| PEG | -3.14 |
| Price to Sales | 0.33 |
| Price to Book Ratio | -2.33 |
| Enterprise Value to Revenue | 0.32 |
| Enterprise Value to EBIT | 1.19 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | -0.49 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 192.00% |
|---|---|
| Total Calls | 314,300▼ 83.31% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.78%▼ 61.62% |
|---|---|
| Total Invested | $14.52M▼ 98.85% |
| Investors Holding | 48▼ 197.00% |
No data
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter ...